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High expression of wee1 is associated with
malignancy in vulvar squamous cell carcinoma
patients
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Abstract
Background: Vulvar squamous cell carcinoma is a cancer form with increasing incidence rate and few treatment
options. Wee1 is a central regulator of the G2/M DNA-damage checkpoint, and has in previous studies been
described as a prognostic biomarker and a potential target for therapy in other cancer forms.
Methods: In the present study we analyzed the expression of Wee1 in a panel of 297 vulvar tumors by
immunohistochemistry. Furthermore, siRNA transfections were carried out in two vulvar cancer cell lines (SW-954
and CAL-39) in order to study the effect on cell cycle distribution (flow cytometry) and proteins (western blot)
involved in DNA damage response and apoptosis.
Results: Wee1 kinase is increased in vulvar squamous cell carcinomas, as compared to expression in normal
epithelium, and a high Wee1 expression is associated with markers of malignancy, such as lymph node metastasis
and poor differentiation. Our in vitro results showed that siRNA mediated Wee1 silencing only led to a modest
reduction in viability, when examined in vulvar cancer cell lines. Nonetheless, a marked increase in DNA damages,
as assessed by augmented levels of γ-H2AX, was observed in both cell lines in the absence of Wee1.
Conclusions: Our results suggest that Wee1 may be involved in the progression of vulvar carcinomas. Based on
our in vitro results, Wee1 is unlikely to function as a target for mono-treatment of these patients.
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Background
Vulvar cancer is a relatively rare malignancy and com-
prises 3-5% of all female genital cancer, however as a
consequence of an aging population the incidence rate
has risen steadily with 20% over the past 40 years [1]. A
total of 4340 new vulvar cancer cases and 940 deaths
from this disease were estimated in the United States in
2011 [2]. The 5-year survival is 98% (stage I), 85% (stage
II), 74% (stage III) and 31% (stage IV) [3]. The incidence
of vulvar cancer has been linked to advancing age, but
also appears in younger women [4]. Radical vulvectomy
with bilateral inguinofemoral lymphadenectomy has
been the standard treatment for most patients, but this
carries significant side effects/burden of morbidity [5].
Therefore, the search for treatment alternatives with less
radical surgery is ongoing. Thus, the identification of
new biomarkers could be important for development of
better treatment strategies and may improve the predic-
tion of clinical outcome.
The Wee1 kinase is a central regulator of the G2/M
cell cycle checkpoint. In cases of DNA damage Wee1
adds an inhibitory phosphorylation on the Tyr15 residue
of CDK1, by so postponing progression to mitosis and
giving the cell time to either correct the damage or
undergo apoptosis [6]. Furthermore, recent studies have
indicated a role of Wee1 in safeguarding the genome
during S- phase, as inhibition of the kinase has led to
replication stress and subsequent DNA damage [7,8].
Whereas the G1/S checkpoint is deregulated in the vast
majority of human cancers, the G2/M checkpoint genes
are rarely, if ever, mutated [6]. Inhibiting proteins in-
volved in the G2/M checkpoint, such as Wee1, may
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therefore selectively target cancer cells whilst sparing
normal cells with a functional G1/S checkpoint. Elevated
levels of Wee1 have been reported in human glioblast-
oma, osteosarcoma, breast cancer and melanoma [9-12],
whilst down-regulation, on the other hand, has been ob-
served in non-small-cell lung cancer [13]. To our know-
ledge, Wee1 in vulvar tumors has not previously been
reported. In the present study our aim was to determine
Wee1 expression in vulvar cancer, if it had an associ-
ation with known clinicopatological variables and bio-
markers, and finally if in vitro targeting of the kinase
may be beneficial as mono-therapy.
Methods
Patient materials
A total of 297 patients were diagnosed with vulvar squa-
mous cell carcinoma between 1977 and 2006 at The
Norwegian Radium Hospital. The median patient age at
diagnosis was 74 (range 35–96) years. Prior to surgery,
three patients received radiotherapy/chemotherapy whereas
another six received radiotherapy. Radical surgery (total
vulvectomy and a bilateral inguinal lymphadenectomy) was
performed in 192 (65%) of these cases and the remaining
105 (35%) patients received non-radical surgery. Postopera-
tive irradiation was given to 63, chemotherapy to three and
irradiation/chemotherapy to four of the patients. After
confirmed diagnosis patients were followed until death or
September 1, 2009. The median follow-up time for patients
still alive was 151 (range; 43 to 378) months. During follow
up, 122 (40%) patients died of vulvar cancer. All lesions
were staged according to the 2009 International Federation
of Gynecology and the Obstetrics (FIGO) classification sys-
tem [14]. The Regional Committee for Medical Research
Ethics South of Norway (S-06012), The Data Inspectorate
(04/01043) and The Social and Health Directorate (04/2639
and 06/1478) approved the current study protocol. In this
study tumor tissue embedded in paraffin blocks from vulvar
cancer patients diagnosed between 1977 and 2006 have
been used. As many of these patients are dead or are very
old, we did not have the opportunity to obtain patient con-
sent. Permission to perform this study without patient con-
sent, was obtained from The Social and Health Directorate
(04/2639).
The histological specimens were reexamined by one
of the authors (J.M.N) according to World Health Orga-
nization recommendations [15]. Two hundred and eighty
(94%) tumors were keratinizing/nonkeratinizing, 13 (5%)
were basaloid and 4 (1%) were veruccoid. As controls,
samples of normal vulva were collected from 10 patients
(age range, 31–65 year) who underwent surgery for benign
gynecological diseases. Results from our previous studies
on cell cycle proteins using the same cohort of vulvar car-
cinomas [16-19] were co-analyzed with those of the
current study.
Immunohistochemstry
Three micrometer sections of formalin-fixed, paraffin-
embedded tissues were stained immunohistochemically
using a Dako EnVision™ Flex + System (K8012; Dako,
Glostrup, Denmark) and a Dako Autostainer. Depa-
raffinization and the unmasking of epitopes were carried
out in a PT-Link (Dako) using an EnVision™ Flex target
retrieval solution at a high pH (Tris/EDTA pH 9). The tis-
sue sections were incubated with a 0.3% hydrogen perox-
ide (H2O2) solution for 5 min to block endogeneous tissue
peroxidase activity. Sections were incubated with mono-
clonal antibody Wee1 (sc-5285, clone B-11, 1:300, 0.67 μg
IgG1/ml, Santa Cruz Biotechnology Inc., Santa Cruz, CA,
USA), and then followed by treatment with EnVision™
Flex +mouse linker (15 min) and EnVision™ Flex/HRP en-
zyme (30 min). The tissues were stained for 10 minutes
with 3′3-diaminobenzidine tetrahydrochloride (DAB),
counterstained with hematoxylin, dehydrated and mounted
in Richard-Allan Scientific Cyto seal XYL (Thermo Scien-
tific, Waltham, MA, USA). All of the sample series included
appropriate positive controls, which included placenta.
Negative control included substitution of the monoclonal
antibody with mouse myceloma protein of the same sub-
class and concentration as the monoclonal antibody.
Two observers (R.H. and J.M.N) evaluated the immuno-
stained slides with no knowledge of patient outcome. All
discordant scores were reviewed until a final agreement
was obtained. Semi-quantitative classes were used to de-
scribe the extent of staining (percent of positive tumor cells:
absent, 0; < 10%, 1; 10-50%, 2; > 50%, 3) and intensity (ab-
sent, 0; weak, 1; moderate, 2; strong, 3). By multiplying the
extent and intensity of the signal, product scores for both
cytoplasm and nuclear staining were produced ranging
from 0 to 9. Protein levels in the nucleus were classified as
high when composite scores were ≥6 and low when com-
posite scores were <6. Protein expression in cytoplasm was
defined as high when any Wee1 staining was observed and
low when no staining was seen. The cutoff value for the im-
munoreactivity was based on staining pattern observed in
normal vulvar epithelium.
Cell lines and growth conditions
Two human vulvar squamous cell carcinoma cell lines,
CAL-39 (DSMZ, Germany) and SW-954 (ATCC,
Manassas, VA, USA) were cultured in Dulbecco’s modi-
fied Eagle Medium (DMEM, Gibco, LifeTechnologies
TM, Invitrogen, Oslo, Norway) supplemented with 10%
Fetal Calf Serum (Biocrom, KG, Berlin, Germany) and
2 mM L-glutamine (LONZA, Vervieres, Belgium) and
Lonza BioWhittaker L-15 (Leibovitz) Medium (Lonza)
containing 20% Fetal Calf Serum and 2 mm L-glutamine,
respectively. Both cell lines were grown in monolayer
culture at 37°C in humidified conditions containing 5%
CO2/95% air (CAL-39) or 100% air (SW-954).
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Small interfering RNA (siRNA) transfection
Both cell lines were plated in either 6-well plates (1.5 ×
105 cells/well) or in 96-well plates (5 × 103 cells/well)
24 hrs prior to the transfection. The cells were
transfected with 25 nM siRNA targeting Wee1
(OligioID; ‘VHS50841’) or RNAi negative control du-
plexes (Negative Control LOW GC, 12935–200) using
LipofectamineTM RNAiMAX transfection reagents (all
reagents from Invitrogen Corporation, CA, USA).
Transfection of cells was performed in Opti-MEM®
(Invitrogen) for 5 hrs and then replaced with the re-
spective growth medium (described above). Cells were
harvested/measured 48 hrs after the transfection was
initiated.
Western blot analysis
Cells were harvested using a rubber policeman, washed
once in 1×PBS, and then lysed in ice-cold NP-40 Lysis
buffer [(1% NP-40, 10% glycerol, 20 mM Tris–HCl
(pH 7.5), 137 mM NaCl, 100 mM NaF), Aprotenin
(0.02 mg/mL), Phosphatase inhibitor cocktail 1 (10 μL/
mL), Phosphatase inhibitor cocktail 3 (10 μL/mL), Phenyl
Methane Sulfonyl Fluoride (PMSF) (1 mM), Leupeptin
(0.02 mg/mL), Pepstatin (0.02 mg/mL) and Sodium vanad-
ate (1 mM) (Sigma-Aldrich, St. Louis, MO, USA)], as pre-
viously described [10]. Bradford (Bio-Rad Laboratories
AB, Sundbyberg, Sweden) analysis was performed for pro-
tein quantification, and 25 μg protein/lane was resolved in
SDS polyacrylamide gel electrophoresis (PAGE) and trans-
ferred to a PDVF immobilon membrane (Millipore,
Bedford, MA, USA). To ensure even loading, filters were
stained with naphtholblue black (Sigma-Aldrich) and later
re-stained with α-tubulin. The membranes were blocked in
5% non-fat milk in TBST (150 mM NaCl, 25 mM Tris-Cl,
(pH 7.5), 0.01% Tween 20), and probed with primary anti-
bodies at 4°C overnight, with gentle agitation. Primary anti-
bodies Caspase 3 (#9662/#9664 (even mix)), p21CIP1/WAF1
(#2946) and PARP (#9532) were purchased from Cell Sig-
naling (Beverly, MA, USA). α-tubulin (DMIB) was acquired
from Calbiochem (Nottingham, UK), whereas Cyclin A (sc-
751), p53 (sc-126) and Wee1 (sc-5285) were obtained from
Santa Cruz Biotechnology. γ-H2AX (#05-636) was pur-
chased from Millipore, and pCDK1Tyr15 (ab47594) and
Cyclin B1 (ab32053) antibodies were acquired from Abcam
(Cambridge, England). Membranes were thereafter washed
3 × 10 min in TBST. The membranes were subsequently
hybridized with an appropriate secondary antibody [HPR-
conjugated anti-rabbit or anti-mouse IgG antibodies
(Promega)] for 1 hr at room temperature, with gentle agita-
tion, and then washed in TBST for 3 × 10 minutes. Protein
bands were visualized after first incubating the membranes
with ECL-plus reagent (GE Healthcare, Chalfont St Gils,
UK) for 5 min.
MTS assay
Five thousand cells per well were seeded in 96-well plates
and left to attach overnight, before siRNA transfection for
the indicated time. Cell viability was determined using the
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium) (MTS) assay (Promega,
WI, USA), in which the capacity of the cells to convert
MTS salt into a brown formazan product was measured.
Absorbance was measured at 490 nm using ASYS
UVM340 96-well plate reader. Absorbance measured from
wells containing medium alone was subtracted, and cell
viability was presented as absorbance relative the control.
Flow cytometric cell cycle analysis
Cells were harvested by trypzination and washed 1 × in
PBS. Cell pellets containing approximately 106 cells were
re-suspended in 1 mL 70% ice-cold methanol and left to
fixate for a minimum of 24 hrs. Fixated cells were washed
1× in PBS, and stained with a solution containing 2 μg/mL
Hoechst 33258 in PBS. Flow cytometric analysis was
performed using LSR II UV laser (BD biosciences, San Jose,
CA), and further processed using FlowJo software (Tree
Star, Ashland, OR, USA).
Statistical analyses
The Pearson’s chi-square (χ2) test was used to study the
relationship between Wee1 expression and clinicopatho-
logic parameters. Disease-specific survival was calculated
from the date of diagnosis to vulvar cancer related death
or September 1, 2009, using the method of Kaplan and
Meier. The log-rank test was used to compare survival
rate. All calculations were processed using SPSS 18.0
statistical software package (SPSS, Chicago, IL, USA)
and statistical significance was considered as P ≤ 0.05.
Results
In normal vulvar squamous epithelium from 10 patients
undergoing surgery for benign gynecological diseases, nu-
clear staining for Wee1 was identified in basal and
parabasal layers (score <6), whereas cytoplasmic staining
was not seen (Figure 1A). The immunostaining results in
vulvar carcinomas are summarized in Table 1. High Wee1
expression (score ≥6) in the nucleus was identified in 77/
297 (26%) of the cases and low levels in 220/297 (74%),
whereas, in the cytoplasm positive Wee1 immunoreactivity
(score >0) was observed in 157/297 (53%) of the tumors
(Figure 1B and C).
In the vulvar carcinoma cell lines SW-954 and CAL-
39 high levels (score ≥6) of nuclear Wee1 immunostain-
ing were observed, additionally, cytoplasmic staining
(score =2) was observed in SW-954 cells (Figure 2).
The levels of Wee1 in relation to clinicopathological
parameters are shown in Table 2. High expression of
Wee1 in the nucleus was significantly correlated with
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younger age (P = 0.01) and presence of lymph node metas-
tasis (P = 0.04). Moreover, high expression of Wee1 in the
cytoplasm significantly correlated with poor tumor differ-
entiation (P = 0.007). High expression of Wee1 in the nu-
cleus significantly correlated with low nuclear and high
cytoplasmic level of phospho-CDC25C (Ser216) (P = 0.002
and P < 0.001, respectively) and high nuclear levels of p21
(P = 0.04) and Cyclin A (P = 0.004). High Wee1 levels in
cytoplasm was significantly correlated with high cytoplas-
mic levels of CDC25C (P = 0.015), 14-3-3β (P =0.008), 14-
3-3ε (P = 0.04) and 14-3-3η (P = 0.003) (Table 3). By
univariate analysis neither nuclear nor cytoplasmic expres-
sion of Wee1 were associated with disease-specific survival
(P = 0.83 and P = 0.63).
The association between high expression of Wee1 and
malignant features in vulvar tumors spurred us to ex-
plore how silencing Wee1 would affect the two vulvar
cancer cell lines; SW-954 and CAL-39. Wee1 protein ex-
pression was effectively removed in both cell lines, along
with a reduced expression of the Tyr15 phosphorylation
of its downstream target CDK1, as determined by west-
ern blotting (Figure 3A). SiRNA mediated silencing of
Wee1 led to a marked increase of γ-H2AX, a specific
marker of double-strand DNA breaks [20]. Despite the
DNA damages, only minute cleavages of the apoptotic
markers Caspase 3 and PARP were found in the absence
of Wee1. In line with this, transfection with siWee1 only
reduced the relative amount of viable cells to approxi-
mately 90% of the control cells (Figure 3B).
Given its role in regulating the cell cycle, we next de-
termined the effect of silencing Wee1 on cell cycle dis-
tribution and some associated proteins. Only subtle
changes in cell cycle distribution were observed follow-
ing siWee1 transfection, with a minute aggregation of
cells in late-S compared to the control cells in both SW-
954 and CAL-39 cells (Figure 4A). The latter cell line
also displayed an increased amount of p21 protein ex-
pression, whereas no changes in p53 levels were seen in
either cell line. Furthermore, an augmented expression
of Cyclin B1 was found in both cell lines in the absence
of Wee1. In SW-954 cells, a weak down-regulation of
Cyclin A was observed (Figure 4B).
Discussion
In the present study we show for the first time that
Wee1 is expressed at a higher level in vulvar squamous
cell carcinomas compared to normal tissue, and that
high expression of the kinase correlates with malignant
features including poor histological differentiation and
lymph node metastases. In accordance with this, high
expression of Wee1 has previously been described in hu-
man glioblastoma, osteosarcoma, breast cancer and mel-
anoma [9-12]. Our previous study with melanomas
showed a similar association between high Wee1 protein
Figure 1 Expression of Wee1 protein in vulvar squamous
epithelium. Immunohistochemical staining of Wee1 in normal
vulvar epithelium (A). High (B) and low (C) expression of Wee1 in
vulvar carcinomas.
Table 1 Immunostaining results for Wee1
Score Nucleus Cytoplasm
N (%) N (%)
0 31 (10) 140 (47)
1 5 (2) 18 (6)
2 38 (13) 67 (23)
3 85 (29) 7 (2)
4 61 (20) 45 (15)
6 68 (23) 16 (5)
9 9 (3) 4 (1)
Total 297 (100) 297 (100)
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expression and markers of malignancy, as found in vul-
var carcinomas [10]. As opposed to our results, a low
expression of Wee1 has been described in different stud-
ies of breast cancer and melanomas, as well as in non-
small-cell lung cancer [13,21,22]. It may be argued that
given the roles of Wee1 in stopping the cell cycle in G2/
M and in restraining CDK activity during S-phase, low
levels of the kinase can possibly facilitate tumor progres-
sion. However, the association between high Wee1 ex-
pression and the presence of lymph node metastasis as
well as poor tumor differentiation found in vulvar can-
cers does not immediately support the tumor suppressor
role of Wee1. Thus, it is possible that Wee1 has a pro-
tective function in vulvar carcinomas. By preventing too
high CDK activity during S-phase, Wee1 may forestall
potentially lethal DNA damages from occurring in the
cancer cells. In agreement with this hypothesis, inhib-
ition of Wee1 has led to reduced proliferation in a range
of cancer cell lines [10,23-25]. Given the divergent re-
ports on the expression of Wee1 in different cancer
forms; the exact role of the kinase in cancer remains
largely unknown. The fact that increased expression of
Wee1 was associated with lymph node metastasis and
poor tumor differentiation indicate that high level of
Wee1 may be involved in malignant progression of vul-
var carcinomas.
The expression of Wee1 and its association with clin-
ical outcome has only been investigated in a few reports,
including one that shows that patients with Wee1 nega-
tive non-small-cell lung cancer had a shorter survival
Table 2 Wee1 expression in relation to clinicopathological
variables
Variables Total Nucleus Cytoplasm
N High (%) P1 High (%) P1
Age 0.01 0.27
25-69 117 41 (35) 68 (58)
70-84 146 27 (18) 74 (51)
85+ 34 9 (26) 15 (44)
FIGO 0.40 0.12
Ia 10 3 (30) 4 (40)
Ib 137 27 (20) 73 (53)
II 13 5 (38) 7 (54)
IIIa 64 22 (34) 27 (42)
IIIb 38 11 (29) 23 (60)
IIIc 12 2 (17) 10 (83)
IVa 5 1 (20) 1 (20)
IVb 13 4 (31) 8 (62)
Not available 5
Lymph node metastasis 0.04 0.52
None 164 36 (22) 87 (53)
Unilateral 89 32 (36) 44 (49)
Bilateral 38 8 (21) 23 (61)
Not available 6
Tumor diameter (cm) 0.34 0.09
0.3-2.5 88 17 (19) 39 (44)
2.6-4.0 93 25 (27) 56 (60)
4.1-20.0 100 28 (28) 55 (55)
Not available 16
Tumor differentiation 0.10 0.007
Well 73 12 (16) 27 (37)
Moderate 153 45 (29) 87 (57)
Poor 71 20 (28) 43 (61)
Depth of invasion (mm) 0.79 0.16
0.0-4.0 76 21 (27) 37 (49)
4.1-8.0 98 24 (24) 60 (61)
8.1-40.0 112 26 (23) 56 (50)
Not available 11
Infiltration of vessel 0.18 0.67
No 229 55 (24) 120 (52)
Yes 65 21 (32) 36 (55)
Not available 3
1Pearson chi-square.
High: Wee1 expression in nucleus ≥ 6 and in cytoplasm > 0.
Figure 2 Expression of Wee1 protein in vulvar cancer cell lines.
Immunohistochemical staining of Wee1 protein in CAL-39 cell line
(A) and SW-954 cell line (B).
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than patients with Wee1 positive cancer in univariate-, as
well as in multivariate analysis [13]. In our present study,
we did not observe any significant association between
disease-specific survival and Wee1 expression for patients
with vulvar carcinomas. Further studies will be needed to
clarify the role of Wee1 as a prognostic marker in human
cancer.
Moreover, we found that the association between Wee1
and different cell cycle regulatory proteins depended on
their cellular localization. A high expression of nuclear
Wee1 correlated with low expression of nuclear- and high
level of cytoplasmic phospho-CDC25C (ser216). These
findings correspond with the hypothesis that in response to
DNA damages, as well as during DNA replication, Chk1
kinase phosphorylates both Wee1 kinase and its comple-
mentary counterpart the phosphatase CDC25C [26]. Once
phosphorylated, the Wee1 protein stabilizes, thus leading to
Table 3 Wee1 expression in relation to cell cycle proteins
Variables1 Total Nucleus Cytoplasm
N High (%) P2 High (%) P2
CDC25C cytoplasm 0.9 0.015
Low (≤ 3) 110 29 (26) 48 (44)
High (> 3) 187 48 (26) 109 (58)
Phospho-CDC25C (Ser216) cytoplasm <0.001 0.18
Low (≤ 3) 147 23 (16) 72 (49)
High (>3) 150 54 (36) 85 (57)
Phospho-CDC25C (Ser216) nucleus 0.002 0.16
Low (−) 86 33 (38) 40 (46)
High (+) 211 44 (21) 117 (55)
14-3-3β cytoplasm 0.7 0.008
Low (≤ 1) 61 17 (28) 23 (38)
High (>1) 236 60 (25) 134 (57)
14-3-3ε cytoplasm 1.0 0.04
Low (≤ 1) 42 11 (26) 16 (38)
High (>1) 255 66 (26) 141 (55)
14-3-3η cytoplasm 0.07 0.003
Low (≤ 3) 138 29 (21) 60 (43)
High (>3) 159 48 (30) 97 (61)
p21 nucleus3 0.04 0.5
Low (−) 119 21 (18) 62 (52)
High (+) 88 26 (30) 50 (57)
Cyclin A nucleus3 0.004 0.2
Low (< 5%) 61 6 (10) 29 (48)
High (≥ 5%) 146 41 (28) 83 (57)
1Have been studied in previous reports [16-19].
2Pearson chi-square.
3207 of the 297 vulvar carcinomas have been tested for this marker.
High: Wee1 expression in nucleus ≥ 6 and in cytoplasm > 0.
Figure 3 DNA damages and reduced viability following SiWee1
transfection in vulva cells. SW-954 and CAL-39 cells were
transfected with either SiCtr or SiWee1 (25 nM) and harvested/
measured after 48 hrs. A. Western blot analysis was conducted
with the indicated antibodies. α-tubulin was used as loading
control. B. Effect of SiWee1 on cell viability as measured by MTS
assay. Error bars represent the standard deviation from four
independent experiments.
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its subsequent nuclear increase. The Ser216 phosphoryl-
ation of CDC25C on the other hand, attracts members of
the 14-3-3 family, which facilitates binding to other pro-
teins such as Chk1, Chk2 and c-TAK1, that can bind to and
relocate CDC25C to the cytoplasm [27]. Based on this, one
could expect the 14-3-3 (β, ε, η) proteins to accumulate in
the cytoplasm along with phospho-CDC25C (ser216),
whilst Wee1 simultaneously would be expressed at a high
level in the nucleus. Instead we observed that high cyto-
plasmic expressions of the 14-3-3 proteins were correlated
with high cytoplasmic Wee1, which does not immediately
support this notion. However, the 14-3-3 proteins are be-
lieved to have several hundred direct binding partners, in-
cluding many central regulators of the cell cycle, and their
cellular localization may thus depend on other factors than
Wee1 [27].
Further on, high nuclear expression of Wee1 was asso-
ciated with high nuclear levels of the S-phase specific
Cyclin A protein in vulvar carcinoma samples. Recent
studies have demonstrated that Wee1 is required to re-
strain CDK1 activity during normal S-phase in order to
prevent unscheduled initiation of replication forks;
hence the kinase expression is thus augmented in this
phase of the cell cycle [28]. The association between
Wee1 and Cyclin A in vulvar cancer could therefore
simply be due to both proteins being expressed in
S-phase. Increased Cyclin A has in a previous study been
suggested to play a role in the pathogenesis of vulvar
squamous cell carcinoma; however no prognostic signifi-
cance was found [18].
Based on its association with malignancy in vulvar carcin-
oma samples, we shut down the expression of Wee1 in two
vulva squamous cell carcinoma cell lines, SW-954 and
CAL-39. The removal of Wee1 protein expression did not
affect cell viability to any substantial extent in either cell
line. Furthermore, there were no major alterations to cell
cycle distribution or cleavage of caspase 3 and PARP,
suggesting that the siWee1 treatment neither led to cell
cycle arrest nor increased apoptosis. In accordance with
these results, inhibition of Wee1 (PD0166285) did not in-
duce cell cycle arrest or cell death when used as mono-
treatment in a study with osteosarcoma cell lines [12]. As
opposed to this, targeting of Wee1 has in itself been suffi-
cient to cause apoptosis and alterations in cell cycle distri-
bution in other cancer cell lines, including melanoma
[10,23,25]. In a study by Iorns et al. where multiple cancer
cell lines were screened with an RNAi library (targeting 779
different kinases) in order to identify genes essential for via-
bility, Wee1 was found as a potential target [11]. However,
only cell lines displaying a high protein level of Wee1 were
responsive to treatment with Wee1 silencing transfections.
In the present study, both SW-954 and CAL-39 cell lines
showed a high expression of Wee1 when assessed by im-
munohistochemistry, but regardless of this trait, removal of
Wee1 did not translate to any major alteration in viability.
Interestingly, despite lack of overall response to siWee1
treatment, a marked increase of γH2AX, indicative of DNA
double-strand breaks, was observed in both cell lines. A
similar increase in DNA damages following removal of
Wee1 activity has been reported in other studies, and
may be explained by the proposed role of the kinase
in safeguarding the genome during DNA replication
[7,8,10,23,25]. Since the vulvar cancer cells did not die or
arrest as a result of accumulating DNA damage, it is pos-
sible that no crucial genes have been affected or that repair
mechanisms are able to correct the damages before the
cells undergo mitosis. In support of the latter hypothesis,
there appeared to be a very slight increase of cells in late-S
phase following knockdown of Wee1. In line with this, an
increased expression of Cyclin B, known to accumulate in
S-phase and stay high until the end of mitosis, was ob-
served in both cell lines after transfection with Wee1 [29].
The anti-tumor effects of inhibiting Wee1 have been shown
as limited to TP53 mutated cell lines in previous studies, in
particular when combined with DNA-damaging agents
[30-32]. The proposed rationale for this selected effect is
that cells with a dysfunctional G1/S DNA-damage check-
point, due to TP53 mutations, are more dependent on
stopping in G2 in order to repair DNA damages before en-
tering mitosis. However, cells with functional p53 have also
been reported to respond to treatment with inhibitors or
siTransfections of Wee1 [10,25]. In a previous study, as
Figure 4 Effects of SiWee1 on cell cycle distribution and on
proteins involved in cell cycle regulation. SW-954 and CAL-39
cells were transfected with either SiCtr or SiWee1 (25 nM) and
harvested after 48 hrs. A. Cells were stained with Hoechst and
cellular DNA content was measured by Flow cytometry. B. Western
blot analysis was conducted with the indicated antibodies. α-tubulin
was used as loading control. Data are representative of three
independent biological experiments.
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many as 44% of vulvar carcinomas were shown to have
TP53 mutations; a large proportion of these also over-
expressed p53 protein due to limited degradation as a con-
sequence of structural alterations of the protein [33]. Both
cell lines used in this study expressed p53, however no al-
terations in the protein expression were observed following
SiWee1 treatment. CAL-39 did nonetheless show an up-
regulation of p21 protein, a downstream target of p53, in
the absence of the kinase.
Conclusion
In conclusion, the association between high Wee1 expres-
sion and presence of lymph node metastasis and poor
tumor differentiation suggest that Wee1 may be involved
in the progression of vulvar carcinomas. However, we
found that Wee1 may not function as mono-treatment in
these patients.
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